A recent study demonstrated that cDC2 are crucial for the initiation of CD4+ T cell-driven anti-melanoma responses and they correlate with a better response to anti-PD-1 therapy; Treg abundance in steady state tumors is a factor limiting the ability of cDC2 to initiate CD4+ T cell responses.43 Our results show that the DC boost approach enhances not only the numbers and activation of intratumoral DC and T cells but also the frequencies of intratumoral Tregs. The gene discussed is PDCD1; the disease is melanoma.